ReviewiLIVER2022

Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review.

Jingxin Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.